International Conference on Biomedical and Cancer Research
  • Follow

Accepted Abstracts

Profile of Chemotherapy-Induced-Severe Neutropenia and Associated Risk Factors among Cancer Patients at the Yaounde General Hospital

Aurelie Hapi Tchuisseu1, Luc-Aimé Kagoue Simeni*1,3, Jean-Thierry Ebogo Belobo 1,6, Etienne Atenguena Okobalemba5, Lawan Loubou Mohamadou1,2,  Sabine Dooh Ngalle1,Yengo Clauvis Kunkeng4, Erwin Ngatcha Tchatchou1, Michel Kengne1,
1Catholic University of central Africa, Cameroon
2Agence Nationale de la Radio-Protection Cameroon
3University Of Buea,Cameroon
4University of Yaounde Cameroon
5Yaounde General Hospital, Cameroon
6Institute of Medical Research and Medicinal Plant Study, Cameroon

Citation: Tchuisseu AH, Simeni LK, Belobo JE, Okobalemba EA, Mohamadou LL (2019) Profile of Chemotherapy-Induced-Severe Neutropenia and Associated Risk Factors among Cancer Patients at the Yaounde General Hospital. SciTech Biomed-Cancer Sciences 2019. Tokyo: Japan

Received: July 16, 2019         Accepted: July 18, 2019         Published: July 18, 2019


AbstractBackground: Neutropenia is a spontaneous complication of chemotherapy. When severe, it is significantly associated with important infectious diseases that increase morbidity, mortality and the cost of management.
Objective: determine the prevalence, incidence, frequency of severe neutropenia in cancer patients treated with chemotherapy and associated risk factors.
Materials and Methods: This was a prospective and descriptive study conducted at the Yaounde General Hospital from January 2016 to December 2017. Neutrophil levels in blood were evaluated before and during chemotherapy treatment. These values ​​were compared to the risk of severe neutropenia in the various subgroups of patients. Statistical analyses were performed using EPI software.                                                                                                                           
Results: Two hundred and seventy-six patients were recruited, 54 were excluded. There were 594 cycles of chemotherapy treatment, ranging from 1 to 4 cycles, with an average of 2.6 cycles per patient. The prevalence of neutropenia before treatment was 19.56% with 0% severe neutropenia. The incidence of neutropenia during treatment was 25% with 22.34% of severe neutropenia (G3 = 16.30%; G4 = 6.04%). The overall frequency of neutropenia was 44.5%, we observed an association between severe neutropenia and lymphocyte count < 1000/mm3 (p value < 0.01), female sex (P = 0.04), chemotherapy (p = 0.01). Lymphopenia was the only independent risk factor (OR: 5.14, CI: 2.34 – 8.24). 
Conclusion: we suggest that lymphopenia < 1000/mm3 as well as Neutropenia <1000/mm3 should be used as a threshold value below which chemotherapy should be contraindicated.
Key words: chemotherapy, severe neutropenia, incidence, prevalence, risk factor